Skip to NavigationSkip to content

News

0
Check out the ten most popular articles on pharmafile.com this week
0
The company had come under some severe scrutiny over the 400% price increase in the injectable since 2008
0
Mylan and Biocon believe that the strength of its data on the bioequivalence compared with the originator will be enough to secure an approval
0
The company only launched in May but has already filed to begin a Phase I trial of a small molecule RIP1 inhibitor

Features

It made headlines last week as a judge ruled that the treatment could be funded by the NHS, but some have labelled it simply a “lifestyle drug”....